- Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
- Aurinia to Participate in Upcoming Investor Healthcare Conferences
- Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
- Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
- Life Sciences Ontario Announces Recipients of 2024 LSO Awards
- Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.99 |
---|---|
High | 5.04 |
Low | 4.97 |
Bid | 4.97 |
Offer | 5.01 |
Previous close | 5.00 |
Average volume | 1.50m |
---|---|
Shares outstanding | 144.62m |
Free float | 133.85m |
P/E (TTM) | -- |
Market cap | 723.09m USD |
EPS (TTM) | -0.5454 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼